Kidswell Bio Corporation

Kidswell Bio Corporation develops pharmaceutical products for pediatric, intractable, and Asia-endemic diseases in Japan. Its pipeline includes GBS-001 and GBS-010 for oncology, GBS-007 for ophthalmic disease, and GBS-011 for renal disease. Additional candidates include GCT-103 for pediatric cerebral palsy, GCT-102 for congenital entero-neuropathy, SQ-104 for osteonecrosis of the femoral head, modified thymidine kinase for glioblastoma, and Gene X for spinal cord injury. Formerly Gene Techno Science Co.,Ltd., it changed its name to Kidswell Bio Corporation in July 2021, was incorporated in 2001, and is headquartered in Chuo, Japan.